KCI requests Developmental Funds in support of: 1) recruitment of new basic and translational investigators;2) innovative projects that bridge several areas of research;and 3) development of Shared Resources (Cores). KCI's Developmental Funds have been used with endorsement of the External Advisory Board and the Senior Leadership of the Cancer Center to enhance the strengths of the current scientific Programs and to increase utilization of the Shared Resources. The Developmental Funds are critical to leverage the support of key Wayne State University stakeholders and local philanthropists. KCI's use of Developmental Funds to support faculty recruitment links with our plan for scientific research investment and supports our continued efforts to grow translational research by increasing interactions among basic scientists and clinicians. The Institute will continue its successful Strategic Research Initiative Grant program and its new Joint Post-Doctoral Training program in order to stimulate projects that have a high potential to go on to program project or SPORE applications. Two new developing Cores are proposed in this application for support from Developmental Funds. The proposed Clinical Imaging Researcii Core promotes imaging in support of cancer detection and therapy and facilitates the integration of functional imaging into routine clinical practice. Finally, the proposed Translational Research Core offers services to develop biochemical, molecular, or cellular assays tailored and validated according to the specific and customized translational research question associated with clinical trials.
Developmental Funds provide support to KCI to: 1) recruit new basic and translational investigators;2) support innovative projects that bridge several areas of research;and 3) support developing Shared Resources (Cores).
|McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130|
|McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177|
|Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095|
|Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :|
|An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605|
|Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963|
|Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55|
|Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56|
|Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703|
|Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58|
Showing the most recent 10 out of 826 publications